Moonlight AI, a Swiss startup constructing picture evaluation software program for clinical-grade diagnostics, has closed a €2.8 million ($3.3 million) Seed funding spherical.
The spherical was co-led by Lotus One Funding (Singapore), VP Enterprise Companions (Switzerland), and MEDIN Fund (Tunisia), with participation from N&V Capital (Liechtenstein) and present investor QAI Ventures (Switzerland).
“Our know-how permits labs to generate actionable, speedy outcomes from slides they already use of their core workflows. By eradicating the necessity for costly {hardware} or guide processes, we’re empowering labs to scale their diagnostic capability and ship sooner outcomes to sufferers,” stated Christian Ruiz, CEO and co-founder of Moonlight AI.
Based in 2022, Moonlight AI specialises in AI-driven diagnostics. It goals to democratise entry to genomic info for correct most cancers diagnostics. The corporate converts medical photos into actionable insights and empowers haematologists and pathologists to make sooner, extra correct remedy choices for most cancers sufferers worldwide.
Based on the corporate, whereas precision oncology depends on entry to genomic information, Subsequent-Technology Sequencing (NGS) stays a bottleneck because of excessive prices and lengthy turnaround instances. Moonlight AI claims to resolve this by utilizing laptop imaginative and prescient to detect genomic biomarkers and complicated illness signatures instantly from routine imaging of blood and cytology smears.
Moonlight’s AI-based diagnostics software program integrates with the diagnostic lab’s imaging {hardware} to enrich and triage molecular testing. The result’s a sooner turnaround time, extra automated workflows, and smarter utilisation of diagnostic sources to serve extra sufferers, says the corporate.
Moonlight AI’s Seed spherical primarily goals to increase its proprietary information library, which is the primary to attach complete slide imaging of cytopathology samples with high-quality genomic information.
Nicole H. Romano, CTO and co-founder of Moonlight AI, stated, “By collaborating with a global consortium of medical companions, we’re curating a dataset that’s poised to help mannequin robustness throughout real-world laboratory settings and affected person populations.”
With this recent funding, Moonlight AI plans to increase its crew, additional develop diagnostic options for myelodysplastic syndrome (MDS), non-small cell lung most cancers, and power lymphocytic leukaemia (CLL). It additionally goals to speed up the trail to commercialisation and regulatory approval.
The funding coincides with Moonlight AI’s transition right into a Swiss Inventory Company (Aktiengesellschaft), positioning the corporate for worldwide enlargement and industrial rollout.
Dr Stefan Habringer, Chief Medical Officer and co-founder of Moonlight AI, “The success of AI‑primarily based diagnostics relies upon essentially on the standard and variety of medical information. We’re subsequently opening our consortium to extra hospitals and laboratories keen on shaping the subsequent era of diagnostics.”
